Table 1.
Baseline characteristics of cohort. The two groups are reasonably matched in terms of demographics as no significant differences (p < 0.05) are observed (two-sided Mann–Whitney U test). With the exception of clinical characteristics (UPDRS Part III score), aAvg. Levodopa Equivalent Daily Dose (LEDD) concerns only PD patients under treatment (n = 13). Additional information, especially for de-novo PD patients can be found in Supplementary Table S1. N.A. not applicable, sig. significant, n.s. non-significant. SU1: SU < 6 months; SU2: SU [6–12] months; SU3: SU > 12 months.
| Characteristics | Early PD patients | Controls | Statistical significance |
|---|---|---|---|
| n (total n = 39) | 22 | 17 | N.A. |
| Demographics | |||
| Women # (%) | 6 (22%) | 7 (41%) | n.s. (p = 0.57) |
| Men # (%) | 16 (78%) | 10 (59%) | n.s. (p = 0.57) |
| Avg. age, years (std) | 58.6 (8.4) | 54.6 (9.4) | n.s. (p = 0.07) |
| Subjects #/# who completed Education Level H/U | 9/13 | 4/13 | n.s. (p = 0.83) |
| Smartphone usage (SU) (SU1/SU2/SU3) | 2/1/19 | 0/0/17 | n.s. (p = 0.29) |
| Clinical characteristics | |||
| Avg. disease onset, years (std) | 2.5 (1.6) | N.A. | N.A. |
| Avg. UPDRS Part III score (std) | 19.7 (14.6) | 1.3 (2.1) | Sig. (p <0.001) |
| PD patients #/# under treatment/de novo | 13/9 | N.A | N.A. |
| Avg. LEDDa, mg (std) | 395 (154) | N.A. | N.A. |
| Avg. valid recordings (std) | 195 (511) | 269 (511) | N.A. |